I n April 2010. the US Food and Drug Administration's (FDA) Advisory Committee for Pharmaceutical Science and Clinical Pharmacy voted 11-2 that the current bioequivalence requirements are not sufficient for narrow therapeutic index (NTI) agents. They also voted 13-0 that the FDA develop a list of NTI drugs with clear criteria for including drugs on the list. The term of a number of members of the committee subsequently expired and new members were replaced. In a July 2011 follow-up meeting, this same Advisory Committee reinforced FDA's proposal to tighten the potency standard for NTI agents.
The Code of Federal Regulations defines narrow therapeutic ratio as the following: ''a. There is less than a 2-fold difference in median lethal dose (LD 50 ) and median effective dose (ED 50 ) values, or b. There is less than a 2-fold difference in the minimum toxic concentration and minimum effective concentrations in the blood, and c. Safe and effective use of the drug products require careful titration and patient monitoring.'' In the United States, a product is bioequivalent if the 90% confidence interval of the geometric mean ratio of area under the curve (AUC) and maximum concentration (C max) between test and reference products fall within limits of 80% to 125%. Health Canada has tightened the AUC criteria for critical agents to 90% to 112%.
The same bioequivalency criteria are currently applied to NTI agents; generic products must have the same quality criteria as the innovator product. Improving quality standards is important for all drugs but especially for those with a narrow therapeutic window. Tightening quality standards will help maintain low variability and consistency of formulation no matter the country of manufacture. In 2010, generic drugs constituted 78% of prescriptions dispensed in the United States. 1 We have all encountered patients who have mentioned inconsistency of response between innovator and generic products. Reducing formulation variability both for agents currently on the market and for new generic applicants is needed.
At the 2010 Advisory Committee meeting, members recommended narrowing the 80% to 125% limits for NTI agents. However, at the most recent meeting, various variability simulations were presented for NTI drugs that included warfarin, levothyroxine, carbamazepine, lithium carbonate, digoxin, phenytoin, and theophylline. The FDA proposed that a scaling approach be used for determination of bioequivalency. Limits would change based on within-subject variability of the reference product. The FDA proposed default limits be 90% to 111% for NTI products and would change based on within-subject variability of the reference product. When reference variability is less than 10%, limits would narrow; if greater than 10%, they would expand but the expansion limits would be capped at 80% to 125%.
Members did not vote on FDA's proposed limits but did support changes in the bioequivalence testing procedures. The impact of additional bioequivalence criteria is also being investigated by the FDA. Currently the FDA is evaluating input received at the recent meeting.
Because bioavailability limits are being considered, potency standards for NTI drugs were also evaluated to improve the safety of these agents. Most potency tests have assay limits of 90% to 110% of reference. Advisors agreed with FDA's proposal to tighten this standard for NTI drugs to 95% to 105% of the reference value. It is hoped that this will not increase product cost due to narrower expiration dating.
The actions of the FDA regarding NTI agents are welcome. Any advances in therapeutic benefit reproducibility between innovator and generic products will also be a benefit to patients.
